Pfizer Inc PFE

$28.72 +0.05 (0.17%)

Valuation

Market cap
163,409,648,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.31
Forward PE
9.54
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
24,950,400
Avg volume
35,986,023
Day's range
$28.39 – $28.87
Shares out
5,699,674,000
Stochastic %K
90%
Beta
0.34
Analysts
Sell
Price target
$28.92

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

BarkingPuppy Sep 29, 4:17 PM
$ELTP $BTC.X $PFE $GME $AMC Elite Pharmaceuticals ($ELTP) is going to be surging into October. I can't spoil the surprise but let me say this, in the end your wife or husband will thank you. Investors will be rallying behind the company's recent pipeline milestones and strengthening generic drug portfolio, pushing shares significantly higher. With key product launches gaining traction, $ELTP is proving to be a micro-cap standout to watch closely right now.
0 replies
Kevin__P Sep 29, 4:01 PM
$PFE Well after 8 straight green days here in a brutal environment this was bound to happen. Any dip buyers today? Thinking about it, but market is tough so I'll watch until it screams "add more" to me LOL.
0 replies
markbrogan Sep 29, 3:55 PM
$PFE Manipulation !
0 replies
PFElinepfrenzy1990 Sep 29, 2:53 PM
$PFE - Spoopy
0 replies
taxplanr Sep 29, 12:42 PM 1 replies
Holdmybagz Sep 29, 10:18 AM
$SPY $MRNA $PFE unvaccinated are not worried https://www.youtube.com/watch?v=Y9afVwQzsF8
1 replies
Agent8 Sep 29, 7:47 AM
$PFE “The company's new and acquired portfolio continues to grow at a solid rate, and Pfizer has also extended commercial runway for the Vyndaqel family, which should offset some of the headwinds in the LOE phase. Management is also taking cost-restructuring initiatives, which should help. Most of the headwinds already seem to be priced in at the current low valuations.” https://seekingalpha.com/article/4950532-pfizer-stock-growth-portfolio-and-cost-cuts-support-buy-through-loe-trough LT
0 replies
RecklessRob1 Sep 29, 6:29 AM
$PFE is this going up like a rocket tomorrow?
3 replies